Philippe STEG, MD
Affiliations
- Chief, Department of Cardiology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, in Paris, France.
- Vice President (in charge of research) of the board of the Assistance Publique-Hôpitaux de Paris network since 2018.
- Professor of Cardiology at Université Paris – Diderot (now Université de Paris), since 1994.
- Visiting Professor, Imperial College, London, UK
- Director of the “Clinical Research in Atherothrombosis” Research Team, INSERM Unit U1148, Paris
- Coordinator of the iVASC (InnoVations in Atherothrombosis SCience) RHU research consortium 2017-2021.
- Chair of the FACT (French Alliance for cardiovascular Clinical Trials) academic research network since 2013.
- Chairman of the French National University Council (Conseil National des Universités) for Cardiology since 2016.
Honors
Dr Steg received the silver medal of the European Society of Cardiology in 2011, the Joseph A Vita Award from the American Heart Association in 2019 and the Grand Prix Claude Bernard de la Ville de Paris in 2019.
Research
Dr Steg has accumulated experience as a clinical trialist in the field of coronary artery disease, diabetes and antithrombotics. He is currently leading several large phase III clinical trials or international registries.
Publications
Dr Steg has authored > 1700 articles in peer-reviewed international journals. His H-Index is 135 (Web of Science) and he has > 115 000 citations. He has been a Thomson Reuters/Clarivate Analytics ”highly cited researcher” in Clinical Medicine every year since 2014. He is Senior Associate Editor for Circulation.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ServierTopic:CLARIFY registryDate added:04/13/2022Relationship end date:01/01/2021
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AmarinTopic:REDUCE IT trialDate added:04/13/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AstraZenecaTopic:Atherosclerosis researchDate added:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AmgenTopic:ConsultingDate added:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:NovartisTopic:Chair Victorion 2P trialDate added:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:JanssenTopic:Chair Milvexian ACS trialDate added:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Novo NordiskTopic:Consulting and speakingDate added:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:SanofiTopic:Consulting and speakingDate added:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:KOWATopic:Steering Committee PROMINENT trialDate added:04/13/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:LEXICONTopic:Chair SCORED trialDate added:04/13/2022